500.com reissued their maintains rating on shares of Amneal Pharmaceuticals (NYSE:AMRX – Get Rating) in a research report released on Monday morning, Benzinga reports.
Several other equities research analysts have also commented on the stock. The Goldman Sachs Group lowered their price target on shares of Amneal Pharmaceuticals from $3.50 to $3.00 and set a buy rating on the stock in a report on Friday, March 3rd. BMO Capital Markets lowered their price target on shares of Amneal Pharmaceuticals from $5.00 to $4.00 and set a market perform rating on the stock in a report on Friday, March 3rd. Piper Sandler lowered their price target on shares of Amneal Pharmaceuticals from $5.00 to $3.00 in a report on Monday. StockNews.com started coverage on shares of Amneal Pharmaceuticals in a research report on Friday, March 17th. They issued a hold rating for the company. Finally, Barclays decreased their price objective on shares of Amneal Pharmaceuticals from $7.00 to $4.00 and set an overweight rating for the company in a research report on Friday, March 10th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus target price of $3.60.
Amneal Pharmaceuticals Price Performance
Shares of AMRX opened at $2.02 on Monday. The firm has a market capitalization of $613.31 million, a PE ratio of -2.24, a price-to-earnings-growth ratio of 0.18 and a beta of 1.33. The company has a debt-to-equity ratio of 14.30, a current ratio of 1.88 and a quick ratio of 1.17. Amneal Pharmaceuticals has a 1-year low of $1.24 and a 1-year high of $3.77. The company’s fifty day moving average price is $1.58 and its 200-day moving average price is $2.04.
Institutional Investors Weigh In On Amneal Pharmaceuticals
Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in Amneal Pharmaceuticals by 1.4% during the 3rd quarter. Vanguard Group Inc. now owns 12,834,345 shares of the company’s stock worth $25,927,000 after buying an additional 181,885 shares during the last quarter. BlackRock Inc. increased its position in Amneal Pharmaceuticals by 1.3% during the 1st quarter. BlackRock Inc. now owns 7,082,702 shares of the company’s stock worth $29,535,000 after purchasing an additional 91,072 shares during the period. Millennium Management LLC grew its holdings in shares of Amneal Pharmaceuticals by 153.3% in the 4th quarter. Millennium Management LLC now owns 5,013,378 shares of the company’s stock worth $9,977,000 after acquiring an additional 3,034,426 shares during the period. Morgan Stanley grew its holdings in shares of Amneal Pharmaceuticals by 935.8% in the 4th quarter. Morgan Stanley now owns 4,220,998 shares of the company’s stock worth $8,400,000 after acquiring an additional 3,813,489 shares during the period. Finally, Neuberger Berman Group LLC grew its holdings in shares of Amneal Pharmaceuticals by 8.1% in the 3rd quarter. Neuberger Berman Group LLC now owns 3,487,919 shares of the company’s stock worth $7,063,000 after acquiring an additional 260,027 shares during the period. 32.79% of the stock is owned by institutional investors and hedge funds.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals.
Further Reading
- Get a free copy of the StockNews.com research report on Amneal Pharmaceuticals (AMRX)
- Is the Electric Vehicle Movement Losing Steam?
- 3 High-Yield Banks Insiders Are BuyingÂ
- Will ChatGPT Be the Final Nail in the Coffin for Chegg?
- Is the Market Reacting Too Negatively to Pinterest Earnings?
- More Analysts Should See Energizer Holdings As A Buy: Here Is Why
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
